Larvol Delta - Evaluating-the-relationship-between-antidrug-antibodies-and-efficacy-and-safety-outcomes-in-patients-with-Fabry-disease-receiving-enzyme-replacement-therapy-a-systematic-literature-review

Elfabrio (pegunigalsidase alfa-iwxj) - Protalix, Chiesi

Fabrazyme (agalsidase beta) - Sanofi

Replagal (agalsidase alfa) - Samaritan Pharma, Takeda

http://www.ncbi.nlm.nih.gov/pubmed/42464344

Derralynn Hughes; John A Bernat; Patrício Aguiar

Jul 18, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next